Core Insights - Overall demand for consumer goods remained relatively weak in July and August, with the seasoning sector affected by the slow recovery in dining demand. However, September showed signs of improvement as dining demand rebounded, leading to a more stable consumption and travel environment during the holiday period [1][2] Group 1: Holiday Performance - During the recent holiday period, key retail and dining enterprises saw a 3.3% year-on-year increase in sales, with an average daily flow of 304 million people, up 6.2% year-on-year, slightly better than previous expectations [2] - The performance of various sectors during the holiday showed differentiation, with snacks leading in overall vitality, followed by beverages, dining chains (seasoning, beer, frozen foods), dairy products, and finally, liquor [2][3] Group 2: Sector Analysis - **Liquor**: Sales during the holiday met expectations, particularly for high-end liquor and banquet scenarios. Post-holiday feedback indicated a 20% year-on-year decline in overall liquor sales, consistent with pre-holiday expectations [3] - **Seasoning**: After a weak performance in July and August, the seasoning sector saw improved sales in September due to the gradual recovery in dining. The holiday period showed a year-on-year increase in sales, driven by the recovery in dining demand [3] - **Dairy Products**: The demand for liquid milk remained weak, with a low single-digit decline expected for major brands. Sales during the holiday were under pressure, with inventory levels remaining relatively healthy [3] - **Beverages**: The beverage sector is entering a slow season, but leading brands continue to perform well. Brands like Nongfu Spring and sugar-free tea maintained good growth, while packaged water continued to gain market share [4] - **Beer**: The beer sector experienced weak downstream demand, particularly in on-premise and dining channels. Companies are increasing investments in instant retail channels to capture new opportunities [4] - **Snacks**: The snack sector continues to show high vitality, benefiting from holiday gifting scenarios. Traditional retail channels saw stable growth in September, with good customer traffic during the holiday [4] - **Frozen Foods**: The frozen food sector saw slight improvements in sales during the holiday, although the overall improvement was limited. Demand for certain products like hot pot ingredients showed some recovery [5]

Core Viewpoint - Geely Automobile (00175) has announced a HKD 2.3 billion share buyback plan, indicating confidence in its long-term development and signaling undervaluation [1] Group 1: Financial Performance - Geely's September sales showed strong performance, with wholesale volume increasing by 35% year-on-year to 273,000 units, setting a historical record [1] - The wholesale volume of new energy vehicles surged by 81.3% year-on-year to 165,000 units, significantly outpacing industry peers [1] Group 2: Strategic Initiatives - The company is implementing an equity incentive plan aimed at enhancing internal management efficiency and supporting strategic execution [1] - The brokerage maintains a target price of HKD 32 for Geely and an "overweight" rating, anticipating that the third-quarter report will validate performance and potentially lead to the company outperforming the industry in the fourth quarter [1]

Core Insights - The new generation trading system developed by China Merchants Securities is the first high-performance trading platform in the securities industry based on a cloud-native architecture, capable of supporting tens of millions of clients [2][3] - The system is designed to handle transaction peaks, with a capacity that can reach over three times historical peak levels, ensuring stable operation even during sudden market fluctuations [3][4] Group 1: System Architecture and Performance - The new system achieves breakthroughs in high resilience, high elasticity, and high agility, as well as full business coverage, localization, and openness [3] - The architecture employs microservices and containerization to minimize the impact of single points of failure, enhancing system maintainability and allowing for flexible business function combinations [4] - A two-site, three-center backup architecture has been implemented, transitioning from traditional single-component reliability to overall system resilience [4] Group 2: Open Ecosystem Development - The cloud-native architecture's openness allows for better integration into the industry ecosystem, promoting standardized and personalized collaborative development [5] - The project took seven years and involved over 100 million yuan in investment, with a focus on innovation despite the lack of precedents in applying cloud-native technology in the securities sector [5] - The system is designed as an open ecosystem platform, allowing for collaboration with various partners and promoting continuous growth [5][6] Group 3: AI Integration and Future Outlook - AI technology is seen as the next significant breakthrough, with the cloud-native architecture providing an ideal foundation for AI applications [7] - The company has established an AI task force to explore the application of large models in securities business, aiming to enhance investment decision-making and reduce behavioral biases [7][8] - A local domestic computing cluster has been established to improve computing efficiency, which is crucial for the commercial viability of AI services [7] Group 4: Regulatory and Compliance Innovations - The company is actively exploring innovations in regulatory compliance, including the establishment of an AI cognitive grading system to provide differentiated services based on investor understanding of AI [8] - A comprehensive auditing and monitoring mechanism is being developed to ensure the safety and controllability of AI applications [8]

截至2025年10月9日收盘，招商证券（600999）报收于17.08元，较前一交易日下跌0.18%，最新总市值 为1485.37亿元。该股当日开盘17.08元，最高17.16元，最低16.86元，成交额达20.31亿元，换手率为 1.61%。 公司于近日发布公告，披露截至2025年9月30日的证券变动月报表。公告显示，招商证券注册股本无变 化。普通股A股于上交所上市，证券代码600999，上月底结存7,422,005,272股，本月无增减，本月底结 存仍为7,422,005,272股，面值人民币1元。普通股H股于香港联交所上市，证券代码06099，上月底结存 1,274,521,534股，本月无增减，本月底结存相同。已发行股份总数未变，无库存股份。注册股本总额为 人民币8,696,526,806元。公司确认本月证券发行符合相关上市规则及法律规定。董事长霍达呈交该报 告。 最新公告列表 《H股公告（截至2025年9月30日止之股份发行人的证券变动月报表）》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - Baofengtang has submitted a listing application to the Hong Kong Stock Exchange, with China Merchants Securities International as the sole sponsor [1] - Baofengtang is a manufacturer of plasma treatment equipment, focusing on the research, development, manufacturing, and sales of plasma treatment equipment for PCB and semiconductor manufacturing [1] - The company's products cover equipment for PCB manufacturing, consumer electronics, and semiconductor packaging, with a business presence in mainland China, Southeast Asia, North America, and Europe [1] Group 2 - According to a Frost & Sullivan report, Baofengtang ranks among the top three in the Chinese PCB plasma stripping equipment market, with an estimated market share of approximately 3.9% in 2024 [1]

Market Outlook - The market is expected to continue the upward trend observed in September, maintaining a low-slope oscillating movement in October, with a high probability of an upward trend due to the low base effect from last year and anticipated earnings growth in most industries [1][2] - The upcoming Fourth Plenary Session and the introduction of the 15th Five-Year Plan are expected to influence market expectations and trading directions, maintaining a high risk appetite in October [2] Industry Recommendations - Key sectors to focus on include non-ferrous metals, power equipment, machinery, automotive, electronics, and media, particularly those with sustained high prosperity and potential for turnaround [1][3][7] - Specific recommendations include industrial metals, precious metals, photovoltaic equipment, batteries, automation equipment, passenger vehicles, semiconductor, consumer electronics, and gaming [3][7] Investment Style and Fund Flows - The market is leaning towards a large-cap style in October, with growth expected to continue to outperform, and a more balanced industry style [3] - There is a positive outlook for net inflows of incremental funds in October, driven by financing funds and continued interest in industry and thematic ETFs [4][5] Economic and Liquidity Conditions - The macro liquidity environment is expected to remain stable, with the central bank maintaining a supportive monetary policy, which is crucial for market stability [4] - The overall funding supply is improving, with a notable increase in the issuance of equity funds and a shift from net redemptions to net subscriptions in ETFs [5] Earnings and Sector Performance - The third-quarter earnings report is anticipated to show significant growth in sectors such as high-end manufacturing, AI industry chain, and essential consumer goods, driven by low base effects and policy support [6][7] - The sectors with the highest expected earnings growth include mid-to-high-end manufacturing, AI-related industries, and certain resource products [6]

呈交日期: 2025年10月8日 致：香港交易及結算所有限公司 公司名稱: 招商證券股份有限公司（「本公司」） 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 第 1 頁 共 11 頁 v 1.1.1 FF301 FF301 本公司乃於中華人民共和國註冊成立的股份有限公司。本公司並無「法定股本」。在上述第I部顯示「法定/註冊股本」的資料是指本公司的「註冊股本」。 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600999 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,422,005,272 | RMB | | 1 RMB | | 7,422,005,27 ...

致：香港交易及結算所有限公司 公司名稱: 招商證券股份有限公司（「本公司」） 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600999 | 說明 | | 於上海證券交易所 （「上交所」）上市之A股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,422,005,272 | RMB | | 1 RMB | | 7,422,005,272 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 7,422,005,272 | RMB | | 1 RMB | | 7,422,005,272 | | 2. 股份分類 | 普通股 | H 股份類別 | | | | 於香港聯交所上市 (註1) | | 是 | | | - ...

Core Viewpoint - The report from China Merchants Securities Hong Kong initiates coverage on HeYue-B (02256) with a "Buy" rating, estimating a fair equity value of HKD 21 billion and a target price of HKD 32.5 for the next 12 months, highlighting the company's long-term growth potential and efficient small molecule development capabilities [1] Group 1: Product Development and Market Potential - HeYue's developed drug, Pimitinib, is expected to be launched in both China and the U.S., providing continuous sales revenue through profit-sharing [1] - The company is actively targeting two significant gene families, FGFR and KRAS, with FGFR4 as a late-stage clinical asset poised to become a new targeted small molecule in liver cancer [1] - The global sales peak for Pimitinib is projected to reach USD 1.5 billion, providing sustained cash flow for HeYue [1] Group 2: Clinical Advancements and Pipeline - HeYue has demonstrated the best efficacy globally for TGCT in the development of CSF-1R inhibitors, with superior safety and response rates compared to similar molecules [1] - The company has received over USD 150 million in cash from its collaboration with Merck, including milestone payments and sales revenue sharing, marking a significant achievement for a Chinese biotech firm in global commercialization [1] - HeYue has a robust pipeline with 22 candidate drugs, including 12 in clinical stages and 10 in preclinical stages, showcasing its leading recognition of frontier targets and clinical development capabilities [3] Group 3: Focus on FGFR and RAS Targets - The company has been deeply engaged in the FGFR target area for ten years, focusing on selective FGFR4 inhibitors and FGFR2/3 inhibitors, addressing unmet needs in liver and gastric cancers [2] - The selective FGFR4 inhibitor, Ipagotinib, is currently in critical Phase III clinical trials, potentially becoming the first approved selective inhibitor targeting FGFR4 globally [2] - HeYue is also developing early-stage molecules targeting G12D and pan-RAS, which will enhance its offerings in precision oncology [2]

Core Viewpoint - The report from China Merchants Securities Hong Kong initiates coverage on HeYue-B (02256) with a "Buy" rating, estimating a fair equity value of HKD 21 billion and a target price of HKD 32.5 for the next 12 months, highlighting the company's long-term growth potential and efficient small molecule development capabilities [1] Group 1: Product Development and Market Potential - HeYue's developed drug, Pimitinib, is positioned as the most effective CSF-1R small molecule globally and is set to launch in both China and the U.S., promising ongoing sales revenue for the company [1] - The company is actively targeting two significant families of important targets, FGFR and KRAS, with FGFR4 as a late-stage clinical asset expected to become a new targeted small molecule in the liver cancer field [1] - The global sales peak for Pimitinib is projected to reach USD 1.5 billion, providing a continuous cash flow for HeYue, with the drug being a key asset in Merck's pipeline [1] Group 2: Clinical Advancements and Pipeline - HeYue has demonstrated the best efficacy globally for TGCT in the development of CSF-1R inhibitors, with safety and response rates surpassing similar molecules [1] - The company has established a robust pipeline with 22 candidate drugs, including 12 in clinical stages and 10 in preclinical stages, showcasing its leading recognition of frontier targets and developing clinical capabilities [3] - The selective FGFR4 inhibitor, currently in pivotal Phase III trials, targets advanced liver cancer patients with FGF19 overexpression, marking a potential first in the global market if successful [2] Group 3: Strategic Focus on Targeted Therapies - The company has been focusing on the FGFR target for a decade, with a deep layout in selective FGFR4 inhibitors and FGFR2/3 inhibitors, addressing unmet needs in liver and gastric cancers [2] - The ongoing research on RAS targets, including early-stage molecules for G12D and pan-RAS, is expected to enhance the company's offerings in precision oncology [2] - The development of next-generation FGFR inhibitors and oral PD-L1 small molecules is anticipated to exceed market expectations through better data disclosure and potential business development transactions [3]